DTX-101

N/A

Report date: 2023/10/26 16:47:07

Base Information

Drug NameDTX-101
Drug Alias NameDTX-101
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh10 vector
Mechanisms of ActionBlood coagulation pathway activationCoagulation factor IX modulatorsFactor IX gene transference
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDimension Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUltragenyx Pharmaceutical Inc
Active IndicationsN/A
Inactive IndicationsHemophilia B

Other Information

ATC CodeN/A
Related LinksN/A